Scarica l'app Stockscreener
71.51
0.53%
0.38
Dopo l'orario di chiusura:
50.34
-21.17
-29.60%
Precedente Chiudi:
$71.13
Aprire:
$70.56
Volume 24 ore:
3.69M
Relative Volume:
1.80
Capitalizzazione di mercato:
$13.21B
Reddito:
$2.53B
Utile/perdita netta:
$-240.23M
Rapporto P/E:
-45.10
EPS:
-1.5857
Flusso di cassa netto:
$-20.46M
1 W Prestazione:
+2.69%
1M Prestazione:
+4.61%
6M Prestazione:
+15.21%
1 anno Prestazione:
+6.70%
Intervallo 1D:
$70.23
$72.83
Intervallo di 1 settimana:
$67.57
$72.83
Portata 52W:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Exact Sciences: Q3 Earnings Snapshot - San Antonio Express-News
After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology - Investing.com
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates - Benzinga
Exact Sciences Corp Q3 2024 Earnings: Revenue at $709M, EPS at -$0.21, Misses Estimates - GuruFocus.com
Exact Sciences shares plummet on weak results, lowered guidance By Investing.com - Investing.com UK
Exact Sciences Announces Third-Quarter 2024 Results - StockTitan
New York State Common Retirement Fund Has $20.19 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday - Yahoo Finance
Exact Sciences Corp (EXAS) Stock Price Up 2.99% on Nov 4 - GuruFocus.com
Exact Sciences to Participate in November Investor Conference - Marketscreener.com
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT - Investing.com
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement - Business Wire
8,360 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Sequoia Financial Advisors LLC - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Screening Sales Drive Exact Sciences' Q3 Earnings? - Yahoo Finance
Exact Sciences Corp (EXAS) Shares Gap Down to $69.69 on Oct 21 - GuruFocus.com
Can This Beaten-Down Cathie Wood Stock Bounce Back? - MSN
Friedenthal Financial Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Cor (EXAS-Q) QuotePress Release - The Globe and Mail
Exact Sciences Corporation (EXAS) Bounced Back in Q3 - Yahoo Finance
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening - Yahoo Finance
Artemis Investment Management LLP Invests $7.27 Million in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences EVP sells shares worth over $65k - Investing.com India
Exact Sciences EVP sells shares worth over $65k By Investing.com - Investing.com Australia
Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares - MarketBeat
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Str - GuruFocus.com
Handelsbanken Fonder AB Acquires 9,400 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Schedules Third Quarter 2024 Earnings Call - BioSpace
Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Exact Sciences Corp - GuruFocus.com
Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish - Investing.com India
FDA greenlights Exact Science’s newest home colorectal cancer test - Medical Device Network
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test - Yahoo Finance
Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio - Insider Monkey
10 Buzzing AI Health Stocks - Insider Monkey
FDA approves Exact Sciences' advanced CRC screening test By Investing.com - Investing.com South Africa
FDA approves Exact Sciences' advanced CRC screening test - Investing.com India
Exact Sciences shares hold as FDA approves new Cologuard test - Investing.com
FDA greenlights Exact Sciences’ Cologuard Plus - BioWorld Online
Exact Sciences shares hold as FDA approves new Cologuard test By Investing.com - Investing.com Canada
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test - Yahoo Finance
Is EXAS Stock a Smart Addition to Your Portfolio Right Now? - Yahoo Finance
Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test - StreetInsider.com
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening - The Bakersfield Californian
Curbstone Financial Management Corp Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.48%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):